Trial | NCT00399204  Report issue

Title

Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients
A Randomised Pilot Study to Compare the Effect of Pioglitazone and Metformin on Cardiovascular Morbidity and Mortality in Patients With Type 2 Diabetes

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Study Participants

    0
The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin
Study Started
Jan 31
2006
Anticipated
Primary Completion
Dec 31
2012
Anticipated
Study Completion
Dec 31
2012
Anticipated
Last Update
Mar 20
2019

Drug Pioglitazone vs Metformin

Control Active Comparator

Metformin

Experimental Experimental

Pioglitazone

Criteria 

Inclusion Criteria:

Newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 25-60 years.
Ready to give written informed consent

Exclusion Criteria:

Presence of ketonuria
Severe concurrent, infection or illness
History of hypersensitivity to any study drug
Impaired renal function
Pulmonary insufficiency with hypoxemia
Severe hepatic disease
Congestive heart failure
History of myocardial infarction or angina(stable/unstable)
History of alcohol or drug abuse
Pregnant or lactating women -
No Results Posted